American Diabetes Association releases guideline update on NAFLD in People with diabetes
Written By : Isra Zaman
Written By : MD Brand Connect
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2023-07-13 05:45 GMT | Update On 2024-08-17 06:33 GMT
Advertisement
Pioglitazone/GLP1 RA are the preferred agents for the treatment of hyperglycemia in people with T2DM diabetes with NAFLD or those at high risk of NAFLD, a recent guidance update released by ADA has stated.
The 2023 ADA guidance update on NAFLD aligns with those of other professional societies, such as AASLD and American Association of Clinical Endocrinology (AACE) and has given a Grade A recommendation to Pioglitazone or GLP1 RA as preferred agents for the treatment of hyperglycemia in T2DM with biopsy-proven nonalcoholic steatohepatitis or high risk NAFLD patients with clinically significant liver fibrosis, along with non-invasive screening guidelines.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.